TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA® (pembrolizumab)
Dateline City:
WALTHAM, Mass., and KENILWORTH, N.J.
Clinical Trial Will Evaluate TESARO’s PARP Inhibitor with Merck’s Anti-PD-1 Therapy in Patients with Breast and Ovarian Cancers
WALTHAM, Mass., and KENILWORTH, N.J., May 30, 2015 – TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a collaboration to evaluate the combination of TESARO’s niraparib plus Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in a Phase 1/2 clinical trial.
Language:
English
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Merck | Ovarian Cancer | Ovaries | Study